Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the chronic obstructive pulmonary disease (COPD) treatment Spiriva will attain sales in the United States, Japan, and Western Europe of approximately $2.8 billion in 2013.

Spiriva (tiotropium) will largely replace Boehringer Ingelheim/Teijin's Atrovent (ipratropium) as an important monotherapy and will represent 34% of major-market sales of $8.4 billion for COPD therapies in 2013, according to the new Pharmacor study Chronic Obstructive Pulmonary Disease. The study also finds that Spiriva will expand the patient population receiving anticholinergics and will likely be used with long-acting beta2 agonists for patients with more-advanced COPD.

"We forecast robust annual growth -- 11.2% -- in the market for COPD therapies from 2003 through 2013 and expect major-market sales to double in 2008 and nearly triple in 2013," said Cari Berg, Ph.D., analyst at Decision Resources. "Successful development of a therapy that halts or significantly alters the course of the disease would revolutionize its treatment and marketplace, but we do not foresee such an event during our ten-year study period."

About Chronic Obstructive Pulmonary Disease

The fourth leading cause of chronic morbidity and mortality in the United States, chronic obstructive pulmonary disease is projected to rank fifth in 2020 as a worldwide "burden of disease," according to estimates from the World Bank/World Heath Organization.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:     Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Open-Access Benefit Models are Reducing HMO Enrollment in TriState Region

View Now